Up a level |
2017
Kraemer, I., Stilgenbauer, S., Dietrich, S., Boettcher, S., Bunjes, D. W., Zeis, M., Stadler, M., Bittenbring, J. T., Uharek, L., Scheid, C., Hegenbart, U., Ho, A., Anthony, D., Hallek, M., Kneba, M., Schmitz, N., Doehner, H. and Dreger, P. (2017). Long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): 10-year follow-up of the GCLLSG CLL3X trial. Bone Marrow Transplant., 52. S. S424 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
2015
Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H. and Goldschmidt, H. (2015). Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia, 29 (8). S. 1721 - 1730. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Scheid, C., Hose, D., Bertsch, U., Hielscher, T., Kunz, C., Salwender, H., Haenel, M., Merz, M., Mai, E. K., Schurich, B., Munder, M., Schmidt-Wolf, I, Gerecke, C., Lindemann, W., Zeis, M., Weisel, K., Duerig, J., Jauch, A., Peters-Regehr, T., Zorn, M. and Goldschmidt, H. (2015). Comparative assessment of myeloma response to induction treatment in the GMMG MM5 study using IMWG criteria and hevylite assay. Oncol. Res. Treat., 38. S. 10 - 11. BASEL: KARGER. ISSN 2296-5262
2014
Mai, E. K., Bertsch, U., Duerig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A., Schurich, B., Hielscher, T., Merz, M., Huegle-Doerr, B., Seckinger, A., Hose, D., Hillengass, J., Raab, M. S., Neben, K., Lindemann, H-W, Zeis, M., Gerecke, C., Schmidt-Wolf, I. G. H., Weisel, K., Scheid, C., Salwender, H. and Goldschmidt, H. (2014). Bortezomib/cyclophosphamide/dexamethasone (VCD) is equally effective and has a favorable toxicity profile compared to bortezomib/doxorubicin/dexamethasone (PAd) as induction therapy in newly diagnosed, transplant-eligible myeloma patients: Results from the multicenter, phase III clinical trial GMMG-MM5. Oncol. Res. Treat., 37. S. 150 - 152. BASEL: KARGER. ISSN 2296-5262